These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8428468)

  • 1. Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group.
    Slotman GJ; Fisher CJ; Bone RC; Clemmer TP; Metz CA
    Crit Care Med; 1993 Feb; 21(2):191-5. PubMed ID: 8428468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study. The Ibuprofen Study Group.
    Haupt MT; Jastremski MS; Clemmer TP; Metz CA; Goris GB
    Crit Care Med; 1991 Nov; 19(11):1339-47. PubMed ID: 1935150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.
    Bone RC; Fisher CJ; Clemmer TP; Slotman GJ; Metz CA; Balk RA
    N Engl J Med; 1987 Sep; 317(11):653-8. PubMed ID: 3306374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.
    Briegel J; Forst H; Haller M; Schelling G; Kilger E; Kuprat G; Hemmer B; Hummel T; Lenhart A; Heyduck M; Stoll C; Peter K
    Crit Care Med; 1999 Apr; 27(4):723-32. PubMed ID: 10321661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.
    Bone RC; Fisher CJ; Clemmer TP; Slotman GJ; Metz CA; Balk RA
    Crit Care Med; 1989 May; 17(5):389-93. PubMed ID: 2651003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study.
    Zeni F; Pain P; Vindimian M; Gay JP; Gery P; Bertrand M; Page Y; Page D; Vermesch R; Bertrand JC
    Crit Care Med; 1996 Feb; 24(2):207-14. PubMed ID: 8605790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction.
    Caliezi C; Zeerleder S; Redondo M; Regli B; Rothen HU; Zürcher-Zenklusen R; Rieben R; Devay J; Hack CE; Lämmle B; Wuillemin WA
    Crit Care Med; 2002 Aug; 30(8):1722-8. PubMed ID: 12163783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study.
    Spies CD; Reinhart K; Witt I; Meier-Hellmann A; Hannemann L; Bredle DL; Schaffartzik W
    Crit Care Med; 1994 Nov; 22(11):1738-46. PubMed ID: 7956276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
    Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
    Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
    Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
    Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study.
    Yu M; Levy MM; Smith P; Takiguchi SA; Miyasaki A; Myers SA
    Crit Care Med; 1993 Jun; 21(6):830-8. PubMed ID: 8504649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study.
    Barton P; Garcia J; Kouatli A; Kitchen L; Zorka A; Lindsay C; Lawless S; Giroir B
    Chest; 1996 May; 109(5):1302-12. PubMed ID: 8625683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group.
    Clemmer TP; Fisher CJ; Bone RC; Slotman GJ; Metz CA; Thomas FO
    Crit Care Med; 1992 Oct; 20(10):1395-401. PubMed ID: 1395659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal and liver function tests in surgical septicemia.
    Smith-Erichsen N
    Acta Anaesthesiol Scand; 1987 Apr; 31(3):208-13. PubMed ID: 3577643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study.
    Rank N; Michel C; Haertel C; Lenhart A; Welte M; Meier-Hellmann A; Spies C
    Crit Care Med; 2000 Dec; 28(12):3799-807. PubMed ID: 11153617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial.
    Boerma EC; Koopmans M; Konijn A; Kaiferova K; Bakker AJ; van Roon EN; Buter H; Bruins N; Egbers PH; Gerritsen RT; Koetsier PM; Kingma WP; Kuiper MA; Ince C
    Crit Care Med; 2010 Jan; 38(1):93-100. PubMed ID: 19730258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
    Abraham E; Naum C; Bandi V; Gervich D; Lowry SF; Wunderink R; Schein RM; Macias W; Skerjanec S; Dmitrienko A; Farid N; Forgue ST; Jiang F
    Crit Care Med; 2003 Mar; 31(3):718-28. PubMed ID: 12626975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.